Candesant Website 1.png
 

Recent Press:

Candesant has developed the Brella™ SweatControl Patch™: an FDA-cleared, non-invasive, topical patch for adults struggling with excessive sweating, including individuals who are bothered by their level of sweat and those who have been officially diagnosed with hyperhidrosis. Candesant’s patch is fast, easy, and effective; it is applied for up to three minutes before being removed, can reduce sweat for up to two months, without the same risk of side effects, need for patient recovery time, or even pain as current treatment options do.

CEO: Niquette Hunt

Headquarters: San Francisco, CA

Year Founded: 2016

Year Avestria First Invested: 2021 (Fund I)

Looking for a job opportunity at Candesant? Click here.

September 23, 2023: Candesant’s Brella™ patch is a winner of the 2023 Allure Best of Beauty Breakthrough Awards. The Award recognize products that “go above and beyond performance - they transform a need in beauty and aesthetic routines and challenge the status quo with a new technology, ingredient, or design.” The winners are selected from hundreds of submissions by Allure’s chemists, clinicians, dermatologists, editors, and other beauty experts. Brella™ is the first in-office sweat control innovation to win a Breakthrough Award.

June 6, 2023: Following the FDA clearance of its Brella™ SweatControl™ Patch, Candesant has raised a $35 million Series B round. The funds will further the commercialization of Brella™, starting with the Brella Early Experience Program later in 2023 and moving onto a national launch in 2024. KCK MedTech led the round with participation by Polaris Partners, Astia Fund, and Correlation Ventures, among others.

April 19, 2023: Doris Day M.D, FAAD, founder of and board-certified dermatologist at Day Dermatology & Aesthetics in New York, sat down with Dermatology Times to discuss primary axillary hyperhidrosis (excessive underarm sweating) and Candesant’s Brella™ SweatControl™ Patch. In the interview, Dr. Day mentions how many patients don’t know that excessive sweating is a medical condition; Brella™ gives dermatologists like her a simple, in-office treatment that works within minutes and has results lasting for months.

April 13, 2023: In this story about Candesant’s Brella™ SweatControl™ Patch. Allure interviews Robert Anolik, MD (a board-certified dermatologist in New York City), Mona Gohara, MD (a board-certified dermatologist in Hamden, Connecticut), and Niquette Hunt of Candesant Biomedical. Their answers explain some of the biggest questions following Candesant’s FDA clearance, including how the patch works, who should get it, and where it will be available.

April 13, 2023: Candesant has announced that its Brella™ SweatControl Patch™ has received de novo clearance by the FDA. The company’s pivotal study showed that participants had a significant reduction in sweat, improvement in quality of life, and no serious or severe adverse side effects - and that the results of three minutes using Brella™ can last three months and even longer than that in some patients. Candesant plans to launch Brella™ in the late summer in select U.S. markets before expanding nationally.

March 18, 2023: After announcing the results of its SAHARA clinical study at the American Academy of Dermatology, Candesant has publicly released the study results - which show that Candesant’s investigational patch significantly reduced underarm primary axillary hyperhidrosis (excessive underarm sweating). Some of the highlights of the study include: 64% of treated participants indicated their sweating never or sometimes interferes with their daily activities (compared to vs. 44% of sham-treated participants), 60% of treated participants showed a 50% or greater reduction in their amount of sweat (compared to 33% of sham-treated participants), and treated participants had a 57 mg mean reduction in gravimetric sweat production (GSP) in five minutes (compared to an 18 mg reduction in five minutes for sham-treated participants).

March 9, 2023: Candesant has announced that its oral presentation of its pivotal clinical trial data will take place in the American Academy of Dermatology (AAD) on March 18. This “late-breaking” presentation may include new data based on Candesant’s clinical trial of its patch - a trial called SAHARA -and analysis of those results. Dr. David Pariser, one of the Investigators for the SAHARA trial, will give the presentation.

December 19, 2022: In this article for Allure, author Kara Nesvig talks about her own experiences with hyperhidrosis or excessive sweating. She talked about how she couldn’t manage getting Botox injections every few months, how she ended up undergoing surgery for sweat glands, and how oral and topical treatments can be irritating or come with side effects. But she highlighted Candesant’s patch as a new way to treat hyperhidrosis without the side effects and inconvenience of previous treatment options. While Candesant’s patch needs continued research, it is a positive start in advancing hyperhidorisis options and restoring quality of life.

October 6, 2022: At the American Society for Dermatologic Surgery (ASDA) Annual Meeting, Candesant introduced its "TAT" (targeted alkali thermolysis) patch and corresponding SweatTech™ Initiative. The SweatTech™ Initiative aims to bring awareness to excessive sweating, potential treatments, and the need for novel treatments, like Candesant’s patch, which is currently under FDA review.

September 22, 2022: This report, published in the November print issue of the journal Dermatologic Surgery, summarizes the results of a randomized, double-blind, sham-controlled showing the performance of Candesant’s "TAT" (targeted alkali thermolysis) patch. Against the sham, participants who used Candesant’s patch saw decreased Hyperhidrosis Disease Severity Scale (HDSS) scores after four weeks and 67% of those participants had a 67% point score reduction. (The sham saw a 0% decrease in HDSS scores.) From this trial, researchers concluded that the TAT patch both “successfully demonstrated efficacy” and “was well-tolerated.”

May 27, 2021: The UCSF Rosenman Institute selected Niquette Hunt as its May Healthtech Leader of the Month. In this written interview, as well as a podcast, Niquette Hunt walks through her journey - from marketing at P&G to the culture shock of working for startups to founding Candesant - and the top three lessons she’s learned along the way.

March 8, 2021: Niquette Hunt was elected to California Life Sciences’ Association (CLSA)’s Board of Directors. CLSA is the state’s largest life science advocacy and business leadership organization, helping to represent the state’s life sciences to its residents, elected officials, and other partners.

October 16, 2020: As medtech analysts mention private companies that they believe investors should watch, Medical Device and Diagnostics Industry (MD+DI) compiled those reports, forming an ultimate list of 20+ companies. Candesant made the list after Marie Thibault, BTIG's Managing Director and Medical Technology & Digital Health analyst, recognized the company in a September report.

September 10, 2020: As part of MedTech Innovator’s virtual accelerator program, Candesant put together a one-minute video to highlight the company and its technology. The top five finalists will be chosen based on YouTube views and likes as well as votes from MedTech Innovator’s selection committee members with the company with the best video winning $10,000.

June 26, 2020: Candesant was one of Medical Design & Outsourcing (MDO)’s 20 medical device startups “you need to know”. Chosen by MDO and MassDevice editors, characteristics of the 20 chosen medical device startups include: a novel use of technology, a minimally invasive approach, and seen improvement in patient outcomes.

June 22, 2020: MedTech Innovation’s flagship four-month showcase and accelerator program chose 50 companies to participate in its flagship four-month showcase and accelerator program, including Candesant. These companies have the opportunity to collaborate with MedTech Innovator’s partners, participate in networking events, and present in showcase panels.

October 25, 2018: Candesant released the results of its clinical study focusing on safety and efficacy in reducing sweat. The CDX-101 STAYDRi.1 study followed subjects for six weeks, finding the average weekly sweat reduction was 69%, the mean sweat production was reduced by 71% by week four, and that 89% of respondents were still showing sweat reduction after six weeks.

Prior page: Axena Health (a Fund II investment)